Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study.

Details

Ressource 1Download: Switch_manuscript_SB_Review_final_accepted.pdf (1119.23 [Ko])
State: Public
Version: Author's accepted manuscript
License: Not specified
Serval ID
serval:BIB_4FD18F26D483
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study.
Journal
Schizophrenia bulletin
Author(s)
Piras M., Ranjbar S., Laaboub N., Grosu C., Gamma F., Plessen K.J., von Gunten A., Conus P., Eap C.B.
ISSN
1745-1701 (Electronic)
ISSN-L
0586-7614
Publication state
Published
Issued date
03/01/2023
Peer-reviewed
Oui
Volume
49
Number
1
Pages
24-33
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Several psychotropic drugs can induce weight gain and metabolic alterations. The authors compared metabolic evolutions of patients switching versus continuing psychotropic treatments with different risk profiles.
Patients either switched from a high- to a medium- (N = 36) or low-risk drug (N = 27), from a medium- to a low-risk drug (N = 71), or to a same-risk drug (N = 61). Controls were kept using either a high- (N = 35), medium- (N = 155), or low-risk drug (N = 47). The evolution over 2 years of weight and metabolic parameters was analyzed using linear mixed-effect models, also examining the influence of polygenic risk scores for body mass index (BMI) or BMI and psychiatric disorders.
High-, medium-, or low-risk controls gained on average 1.32%, 0.42%, and 0.36% more weight per month than patients switching from or within these risk categories (P < .001, P < .001, and P = .003, respectively). High-to-high or high-to-medium switches resulted in a greater weight increase than switching to lower-risk categories (+0.77% and + 0.39% respectively, P < .001). No difference was found between switching medium-to-medium and medium-to-low (P ≈ 1). Switching high-to-low resulted in 10% weight loss after 2 years, with the greatest loss occurring the first 6 months after the switch. Compared with high-risk controls, lower total cholesterol (-0.27 mmol/l, P = .043) in the high-to-low group, and lower glucose (-0.44 mmol/l, P = .032) and systolic blood pressure (-5.50 mmHg, P = .034) in the low-to-low group were found. Polygenic scores were not associated with weight changes in controls or after switching.
Psychotropic switches to a lower- or same-risk drug can attenuate weight gain, with only switching high to low resulting in weight loss.
Keywords
Humans, Longitudinal Studies, Psychotropic Drugs/adverse effects, Weight Gain, Cohort Studies, Weight Loss, metabolic risk, psychotropic switch, weight gain
Pubmed
Web of science
Create date
03/10/2022 14:48
Last modification date
25/05/2024 7:12
Usage data